| Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout Nonsteroidal Anti-inflammatory Drugs (NSAIDs)   
| Anti-inflammatory effects: ↓ Platelet aggregation, interferes with kallikrein system, ↓Granulocyte adherence to    damaged vasculature, ↓Chemotaxis of PMNs & macrophages   Anti-platelet: ↓ COX-1 & COX-2 Analgesic effects Antipyretic effects: ↓ COX & IL-1 | Gastric upset, gastric/duodenal ulcers, hepatotoxicity, asthmatic attacks, rashes, renal toxicity   High doses: salicylism (vomiting, tinnitus, ↓ hearing, vertigo)     | Used for anti-platelet effect: ↓ incidence of ischemic attacks, unstable angina, coronary artery thrombosis with MI, thrombosis after coronary bypass surgery |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout Nonsteroidal Anti-inflammatory Drugs (NSAIDs)   
| Selectively inhibits COX-2 | Renal toxicity  ↑ risk of thrombotic events GI upset, peptic ulcers | Fewer GI effects and doesn’t affect platelet aggregation; no cardioprotective effects |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout Nonsteroidal Anti-inflammatory Drugs (NSAIDs)   
| Reversibly inhibits both  COX-1 & COX-2 | Less fluid retention & GI ulcers GI upset, peptic ulcers | Close the patent ductus arteriosus, analgesia Anti-inflammatory and anti-platelet action ↓ when used with aspirin |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout Nonsteroidal Anti-inflammatory Drugs (NSAIDs)   
| Nonselective COX inhibitor Inhibit phospholipase A & C Reduce neutrophil migration ↓ T cell & B cell proliferation   | Pancreatitis, headache (25%), psychosis (rarely), thrombocytopenia, aplastic anemia, renal papillary necrosis GI upset, peptic ulcers | Close the patent ductus arteriosus, gout |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout Disease-Modifying Anti-Rheumatic Drugs (DMARDs)   
| Inhibits AICAR* transformylase & thymidate synthase   Affects PMN chemotaxis, DHF reductase, ↓ proinflammatory cytokines | Nausea, mucosal ulcers, hepatotoxicity   CI in pregnancy | Rheumatoid arthritis (1st choice)   Juvenile chronic arthritis, psoriasis, ankylosing spondylitis, polymyositis, Wegener’s granulomatosis, lupus, vasculitis |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout Disease-Modifying Anti-Rheumatic Drugs (DMARDs)   
| Inhibits interleukin-1 and 2 receptor production => inhibits macrophage-T-cell interaction and T-cell responsiveness | Nephrotoxicity  Hyptension, hyperkalemia, hepatotoxicity, gingival hyperplasia, hirsutisim | rheumatoid arthritis (↓ new bony erosions) |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout Disease-Modifying Anti-Rheumatic Drugs (DMARDs)   
| Inhibits dihydroorotate dehydrogenase leading to ↓ ribonucleotide synthesis and arrest of cells in G1 phase =>  ↓ T-cell proliferation and production of autoantibodies by B cells   ↑ IL-10 receptor mRNA, ↓ IL-8 receptor type A mRNA, ↓ TNF-α-dependent NF-κB | Diarrhea (25%), ↑ liver enzymes Mild alopecia, weight gain, ↑BP   CI in pregnancy | Rheumatoid arthritis (inhibit bony damage) |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout Disease-Modifying Anti-Rheumatic Drugs (DMARDs)   
| Inhibits CMP dehydrogenase => ↓T-cell proliferation   Interferes w/ WBC adhesion via E&P selectins and ICAM-1 | Nausea/vomiting, hypertension, reversible neutropenia | Renal disease, vasculitis, Wegner's granulomatosis, Lupus |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout Disease-Modifying Anti-Rheumatic Drugs (DMARDs)   
| ↓ T-cell response to mitogens ↓ leukocyte chemotaxis ↓ DNA/RNA synthesis Trap free radicals | Ocular toxicitydyspepsia, nausea, vomiting, abdominal pain, rashes, nightmares
 | Malaria, rheumatic disease |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout Disease-Modifying Anti-Rheumatic Drugs (DMARDs)   
| Inhibit immune response | Pigmentation changes (anti-rheumatic gold containing compounds) | No longer used due to toxicity & questionable efficacy |    |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout TNF-α Inhibitors   
| Human IgG1 anti-TNF antibody that complexes with TNF-α and prevents its interaction with p55 and p75 cell surface receptors => ↓macrophage and T-cell | ↑risk of bacterial and macrophage-dependent infection (including TB and other opportunistic infections) | Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile idiopathic arthritis, plaque psoriasis, Crohn’s disease |  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout TNF-α Inhibitors   
| Chimeric IgG1 antibody that binds to soluble and bound TNF-α => ↓macrophage and T-cell function | ↑incidence of bacterial infections (including upper respiratory), activation of latent TB | Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease |  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout TNF-α Inhibitors   
| Fusion protein made of 2 soluble TNF p75 receptor moieties linked to Fc of human IgG1; binds TNF-α and inhibits lymphotoxin-α | ↑bacterial infections, especially soft tissue infections and septic arthritis, may activate latent TB | Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, juvenile chronic arthritis, psoriasis |  |  | 
        |  | 
        
        | Term 
 | Definition 
 
        | CH 36 NSAIDs, Antirheumatic Drugs, Nonopioid Analgesics, & Drugs Used in Gout   
| Weak COX 1 and 2 inhibitor in peripheral tissue Antipyretic and analgesic, but NO anti-inflammatory or platelet aggregation inhibition | ↑ hepatic enzymes   Overdose: Hepatotoxicity with centrilobular necrosis, acute  renal tubular necrosis | Treat moderate pain without anti-inflammatory effect Preferred over aspirin for children with viral infections hemophiliacs, ulcer-prone patients, gout |    |  | 
        |  |